SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007898
Filing Date
2022-05-05
Accepted
2022-05-05 16:43:45
Documents
64
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cyt-20220331.htm   iXBRL 10-Q 1535191
2 EX-31.1 cyt-ex31_1.htm EX-31.1 20002
3 EX-31.2 cyt-ex31_2.htm EX-31.2 19978
4 EX-32.1 cyt-ex32_1.htm EX-32.1 11531
5 EX-32.2 cyt-ex32_2.htm EX-32.2 11517
  Complete submission text file 0000950170-22-007898.txt   5710395

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20220331_lab.xml EX-101.LAB 359306
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20220331_pre.xml EX-101.PRE 258288
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20220331.xsd EX-101.SCH 41686
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cyt-20220331_cal.xml EX-101.CAL 40845
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cyt-20220331_def.xml EX-101.DEF 135682
58 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20220331_htm.xml XML 939773
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

IRS No.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40499 | Film No.: 22897171
SIC: 2834 Pharmaceutical Preparations